METOPROLOL-L TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

METOPROLOL TARTRATE

Verfügbar ab:

MELIAPHARM INC

ATC-Code:

C07AB02

INN (Internationale Bezeichnung):

METOPROLOL

Dosierung:

100MG

Darreichungsform:

TABLET

Zusammensetzung:

METOPROLOL TARTRATE 100MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100/500/1000

Verschreibungstyp:

Prescription

Therapiebereich:

BETA-ADRENERGIC BLOCKING AGENTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0111923003; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2014-06-25

Fachinformation

PRODUCT MONOGRAPH
Pr
METOPROLOL-L
(Metoprolol Tartrate Tablets, USP)
25 mg, 50 mg and 100 mg
ß-Adrenergic Receptor Blocking Agent
MELIAPHARM INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
Date of Revision:
March 5, 2014
Submission Control No: 172541
METOPROLOL-L _Product Monograph _
_Page 2 of 40_
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
....................................................................................3
INDICATIONS AND CLINICAL USE
..........................................................................................3
CONTRAINDICATIONS
...............................................................................................................4
WARNINGS AND PRECAUTIONS
..............................................................................................5
ADVERSE REACTIONS
..............................................................................................................10
DRUG INTERACTIONS
..............................................................................................................13
DOSAGE AND ADMINISTRATION
..........................................................................................17
OVERDOSAGE
............................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
........................................................................21
STORAGE AND STABILITY
......................................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................................................24
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
......................................................................................26
DETAILED PHARMACOLOGY
......................